Akorn shareholders approve merger with Fresenius Kabi
LAKE FOREST - Akorn Inc. shareholders have overwhelmingly voted to approve the company's acquisition by Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA.
The transaction remains subject to regulatory approvals and customary closing conditions, and the companies expect the acquisition will close by early 2018.
Fresenius Kabi announced in April it would acquisition of Lake Forest-based generic drugmaker for $4.3 billion. Fresenius will get a stronger foothold in the U.S., with access to a network of retail pharmacies and outpatient clinics as well as the hospitals where it has traditionally marketed its products.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.